Effect of rosiglitazone and nateglinide on serum glucose and lipid profile alone or in combination with the biguanide metformin in diabetic rats.
This study was designed to investigate the effect of 1 month treatment with nateglinide, rosiglitazone, metformin and their different combinations on streptozotocin (STZ) diabetic rats.


METHODS
Diabetes was induced by a single intraperitoneal injection of STZ at a dose 55 mg kg(-1). The plasma glucose, total lipid, cholesterol, triglyceride and protein components were measured before and 15 and 30 days after the administration of the antidiabetic agents.


RESULTS
After the treatment, a significant reduction was observed in fasting blood glucose levels in all groups. Rosiglitazone or metformin were found to exhibit a hypolipidaemic effect in diabetic rats when administered alone or in combination. In comparison, nateglinide, when used alone, resulted in a significant increase in cholesterol and total lipid levels. This effect was masked when nateglinide was administered concurrently with metformin and hypolipidaemic effect was noticed.


CONCLUSIONS
Results from this study suggest that compared with nateglinide, rosiglitazone has a more favorable effect on the lipid profile in STZ-induced diabetes in rats.
El-Batran
Seham A
SA
Department of Pharmacology, National Research Center, Dokki, Cairo, Egypt. Sehamelbatran@yahoo.com
Abdel-Salam
Omar M E
OM
Nofal
Salwa M
SM
Baiuomy
Ayman R
AR
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism*; D001798:Blood Proteins / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D003510:Cyclohexanes / Q000008:administration & dosage / Q000627:therapeutic use*; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D050356:Lipid Metabolism / Q000187:drug effects*; D008055:Lipids / Q000097:blood; D008297:Male; D008687:Metformin / Q000008:administration & dosage / Q000627:therapeutic use*; D000077715:Nateglinide; D010649:Phenylalanine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000008:administration & dosage / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D001786:Blood Glucose; D001798:Blood Proteins; D003510:Cyclohexanes; D007004:Hypoglycemic Agents; D008055:Lipids; D045162:Thiazolidinediones; D014280:Triglycerides; D000077154:Rosiglitazone; D000077715:Nateglinide; D010649:Phenylalanine; D008687:Metformin; D002784:Cholesterol